Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY – Free Report) from a hold rating to a buy rating in a research report report published on Saturday morning.
Several other analysts also recently issued reports on SNY. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $49.50.
Read Our Latest Research Report on SNY
Sanofi Stock Down 0.0%
Sanofi (NASDAQ:SNY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $13.36 billion for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The company’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.24 EPS. Equities research analysts forecast that Sanofi will post 5.01 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Physician Wealth Advisors Inc. increased its holdings in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after purchasing an additional 379 shares during the last quarter. Leonteq Securities AG boosted its stake in shares of Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after buying an additional 297 shares during the last quarter. Western Wealth Management LLC acquired a new stake in shares of Sanofi during the first quarter worth approximately $29,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Sanofi during the third quarter worth approximately $29,000. Finally, Palisade Asset Management LLC bought a new stake in shares of Sanofi in the third quarter worth $30,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.
About Sanofi
Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
Read More
- Five stocks we like better than Sanofi
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
